$JKHY

JACK HENRY & ASSOCIATES INC (JKHY): Results of Operations and Financial Condition

JACK HENRY & ASSOCIATES INC (JKHY) filed an SEC Form 8-K — Results of Operations and Financial Condition. jkhy-20260811 0000779152 2026 FY FALSE 0000779152 2026-08-11 2026-08-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event re

Original reporting
Published Aug 11, 2026, 9:24 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$JKHY
Neutral
low confidence
Mentioned
$JKHY
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$JKHYNeutralLow
01

Why it matters

The market impact depends on how deconversion revenue performed for fiscal Q4 and full FY ended June 30, 2026, and whether management provided any additional commentary in Exhibit 99.1.

02

Market read

This is a routine but primary-source financial disclosure. The excerpt confirms the filing and attachment but not the figures, so actionable interpretation requires reviewing Exhibit 99.1.

03

What to watch

The attached press release likely contains the key deltas (revenue amount, drivers, and any outlook). Without those, the trading signal cannot be validated.

Relevance 7/10Novelty 4/10Timing: filed after market close, dated Aug 11, 2026

Background

The filing is a SEC Form 8-K under Item 2.02, indicating results of operations and financial condition, with Exhibit 99.1 containing the company’s press release.

Company-level read

Ticker impact

$JKHYNeutralLow confidence
Context

JKHY filed an 8-K for Item 2.02, attaching its press release on deconversion revenue for the fiscal Q4 and full FY ended June 30, 2026.

Expected impact

Near-term price reaction is possible once the attached Exhibit 99.1 figures are reviewed, but direction cannot be inferred from the provided text.

Evidence & confidence

The body confirms the filing and that a press release is attached, yet it provides no numeric results, comparisons, or forward-looking statements in the excerpt.

Market effects

Limited from the excerpt; any read-through would depend on the deconversion revenue magnitude versus prior periods.

None indicated in the provided text.

None indicated in the provided text.

Counterpoint

Because the excerpt omits the actual financial numbers, traders may overreact to the filing itself rather than the substance in Exhibit 99.1.

Key entities

  • Jack Henry & Associates, Inc.

    Subject of the 8-K filing, reporting deconversion revenue results for fiscal Q4 and full FY ended June 30, 2026 via Exhibit 99.1.

  • SEC Form 8-K

    The vehicle for the disclosure, specifically Item 2.02 results of operations and financial condition.

Related articles

$JKHYMedAI 8/10

JACK HENRY & ASSOCIATES INC (JKHY): Results of Operations and Financial Condition

JACK HENRY & ASSOCIATES INC (JKHY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 jkhy-20260630xex99pressrel.htm EX-99.1 - JKHY - 2026.06.30 - Q4 FY26 PRESS RELEASE Document Press Release Mimi L. Carsley | Chief Financial Officer | mcarsley@jackhenry.com FOR IMMEDIATE RELEASE Jack Henry & Associates, Inc. Reports Fourth Quarter and Full Year Fiscal 2

$FOCLMedAI 8/10

FocalTherics (FOCL) Q2 2026 Earnings Call Transcript

FocalTherics (FOCL) reported Q2 2026 earnings with $13.2M in HIFU revenue, up 39% YoY. They sold 13 Focal One systems, a 44% increase. The company expanded its footprint in the U.S. and internationally, including sales to Cleveland Clinic and Kaiser Permanente. They submitted a 510(k) application for FocalConnect and expect CMS reimbursement increases. The company is also expanding into new indications like BPH and endometriosis, targeting a $10B revenue opportunity.

$CSANMed

Cosan Q2 Earnings Call Highlights

Cosan reported a debt service coverage ratio of 0.2x, down from the prior quarter, and expects it to reach 0.8x-1.2x by year-end. The company plans to delist its ADS from the NYSE and reduce overhead. Investees showed mixed performance, with Rumo's EBITDA stable, Compass up 5%, and Moove down 6% YoY. Cosan is pursuing divestments, including a stake in Terminal de Uso Privado Porto São Luís for BRL 300M.